Latanoprost/netarsudil mesylate - Aerie Pharmaceuticals

Drug Profile

Latanoprost/netarsudil mesylate - Aerie Pharmaceuticals

Alternative Names: Latanoprost/AR-13324; Netarsudil/latanoprost ophthalmic solution - Aerie Pharmaceuticals; PG324; Roclatan

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aerie Pharmaceuticals
  • Class Antiglaucomas; Prostaglandins
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors; Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 08 Nov 2017 Aerie Pharmaceuticals plans a regulatory filing in Europe
  • 06 Sep 2017 Phase-III clinical trials in Glaucoma in Belgium and Spain (Ophthalmic) (EudraCT2015-001528-41)
  • 06 Sep 2017 Phase-III clinical trials in Ocular hypertension in Belgium and Spain (Ophthalmic) (EudraCT2015-001528-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top